ing. J.K. (Marc ) Jorissen
ing. J.K. (Marc ) Jorissen
- Department of Epidemiology
- Julius Center Research Program Infectious Diseases
Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002 and as clinical microbiologist in 2008, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.
He is scientific Director of the research theme "Tackling Antimicrobial Resistance" of the Netherlands Centre for One Health (NCOH; www.ncoh.nl). (2016-)
He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)
Coordinator of the H2020-funded project ECRAID-Base (March 2021-) and Chief Executive Officer of the ECRAID foundation (Jan 2022-)
Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)
Advisory boards, DSMBs and steering committees
Chair of international study steering committee EMBRACE study, Janssen Vaccines; payments to UMC Utrecht) (2017-);
Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal vaccination, Sanofi Pasteur (payments to UMC Utrecht) (2019-)
Advisory Board clinical development ensovibep for treatment COVID-19 (international), Novartis (payments to UMC Utrecht) (2022-)
Advisory Board clinical development for bactriophage therapy (international), Pherecytes (payments to Ecraid) (2022-)
Advisory Board pneumococcal vaccination (international), Merck Sharp & Dohme BV (payments to UMC Utrecht) (2020-)
Board member "stichting ter bevordering van onderzoek en onderwijs op het gebied van intensive care geneeskunde en infectieziekten". Unpaid. No recent activities.
Advisory Board Covid-19 treatment (national), AstraZeneca (payments to UMC Utrecht) (2021);
Advisory Board pneumococcal vaccination (international), Pfizer (payments to UMC Utrecht) (2021);
Takeda (Nov 2019) (payments to M. Bonten)
Netherlands Veterinary Medicines Institute (SDa) (2019-) (payments to UMC Utrecht).
Cluster Infectieziektenbestrijding from ZorgOnderzoek Nederland (2019-) (attendance fees to UMC Utrecht).
Scientific Advisory Board of GARDP (Global Antibiotic Research & Development Platform (2020-) (no payments).
Advisory Panel Innovative Treatments COVID-19 of the Ministry of Health, Welfare and Sport (2020-) (attendance fees to UMC Utrecht).
Outbreak Management Team for COVID-19 (2020-) (attendance fees to UMC Utrecht)
Research activities: contract research
UMC Utrecht coordinates in the Netherlands the HERALD study; A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older een fase2/3 studie. Study sponsor: CureVac. Bonten is principal investigator for the Netherlands. (2020-) (no personal payments)
UMC Utrecht executes the EMPATHY study; a randomized double-blind placebo-controlled multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. Study sponsor: Novartis & Molecular partners. Bonten is principal investigator for UMC Utrecht. (2021-) (no personal payments)
UMC Utrecht is a study site in the VAC31518COV2001 study; a phase 2 randomized double-blind placebo-controlled multicenter study of the COVID-19 vaccine from Janssen Vaccines. Study sponsor: Janssen Vaccines. Bonten is principal investigator for UMC Utrecht. (2020-) (no personal payments)
UMC Utrecht is a study site in the E.mbrace study; a phase 3 randomized double-blind placebo-controlled study of a 12-valent E. coli vaccine from Janssen Vaccines. Bonten is principal investigator for UMC Utrecht. (2022-) (no personal payments)
UMC Utrecht cordinates the PNEUMO study: an international observational study to quantify sero-type specific incidence of pneumococcal infections. Study sponsor: Merck. Bonten is principal investigator. (2018-) (no personal payments)
UMC Utrecht collaborates with Limmatech on exploring possibilities to study vaccination for Klebsiella infections. (2021-) (no personal payments)
Ecraid executes the open-label phase 2/3 clinical study to investigate safety and immunogenicity of a single VLA2100 booster vaccination in adult volunteers, after receipt of nationally rolled out mRNA COVID-19 vaccines and/or natural SARS-CoV2 infection. Study sponsor: Valneva Austria GmbH. Bonten is principal investigator. (2022-) (no personal payments)
Ecraid assists Spherecytes in the execution of PhagoDAIR I: A pilot, multicenter, randomized, non-comparative, double-blind study of phage therapy in patients with hip or knee prosthetic joint infection due to Staphylococcus aureus treated with DAIR and antibiotic therapy. (no personal payments)
UMC Utrecht executed the CAPiTA study and 3 related observational studies with PCV13 (2007-2014). Bonten performed until 2016 - on request of Pfizer - presentations on the results of these studies. Payments to UMC Utrecht. (no personal payments)
Research activities: public private partnerships (PPP) funded through the Innovative Medicine Initiative (IMI)
Bonten is, on behalf of UMC Utrecht, coordinator of COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET en COMBACTE-CDI) with the aim to improve efficiency of clinical evaluation of new antimicrobial treatments. Collaboration in this PPP is with AstraZeneca, Pfizer, GSK, Basilea, AiCuris, DaVolterra, Janssen, Sanofi, BioMerieux and MSD (www.combacte.com). (2013-) COMBACTE CDI ended in 2021. (no personal payments)
Bonten is, on behalf of UMC Utrecht, co-coordinator of the PPP VITAL in which the effects of aging on vaccine response is investigated. Collaboration in this PPP is with Pfizer, GSK, Janssen, Sanofi, BioMerieux en MSD (https://vital-imi.eu/). (2017-) (no personal payments)
Bonten is, on behalf of UMC Utrecht, scientific coordinator of the PPP PrIMAVera (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) in which the potential effects of monoclonal antibodies and vaccines on the epidemiology of antimicrobial resistance will be investigated. Collaboration in this PPP is with GSK and Janssen. (2021-) (no personal payments)
UMC Utrecht is partner in VALUE-Dx in which the effects of diagnostics in the treatment of respiratory tract infections is investigated. Collaboration in this PPP is with BioMerieux, Abbot, Janssen, BioRad en BD (https://vital-imi.eu/). Bonten co-leads the ADEQUATE study in which collaboration is with BioMerieux. (2019-) (no personal payments)
Fellowship and Awards
He is a VICI laureate (2006) from the Dutch Science Association, Principal Investigator of the CAPiTA study, coordinator of the EU-funded project R-GNOSIS, scientific coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET. He is member of the International Trial Steering Committee of the REMAP-CAP study, and coordinator of ECRAID-Base.
In 2015 he received the ESCMID 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases.
In 2017 he received a honorary fellowship of the Royal College of Physicians of Ireland, and was awarded the ESCMID fellowship.
In 2021 he was elected member of the Koninklijke Nederlandse Academi voor Wetenschappen.
Research Output (776)
Hullegie Saskia, Venekamp Roderick P, van Dongen Thijs M A, Mulder Sanne, van Schaik Willem, de Wit G Ardine, Hay Alastair D, Little Paul, Moore Michael V, Sanders Elisabeth A M, Bonten Marc J M, Bogaert Debby, Schilder Anne Gm, Damoiseaux Roger A M J 16 Dec 2021, In: BMJ Open. 11
Peters-Sengers Hessel, Butler Joe M, Uhel Fabrice, Schultz Marcus J, Bonten Marc J, Cremer Olaf L, Scicluna Brendon P, van Vught Lonneke A, van der Poll Tom, 13 Dec 2021, In: Intensive Care Medicine. 48 , p. 92-102 11 p.
Pham Thi Mui, Tahir Hannan, van de Wijgert Janneke H H M, Van der Roest Bastiaan R, Ellerbroek Pauline, Bonten Marc J M, Bootsma Martin C J, Kretzschmar Mirjam E Dec 2021, In: BMC Medicine. 19 , p. 1-16
Pereverzeva Liza, Uhel Fabrice, Peters Sengers Hessel, Cremer Olaf L, Schultz Marcus J, Bonten Marc M J, Scicluna Brendon P, van der Poll Tom, Dec 2021, In: Annals of Intensive Care. 11 , p. 1-13 13 p.
van Dongen Josephine A P, Rouers Elsbeth D M, Schuurman Rob, Band Caterina, Watkins Shannon M, van Houten Marlies A, Bont Louis J, Norbruis Obbe F, Hemels Marieke A C, van Well Gijs T J, Vlieger Arine M, van der Sluijs Jacqueline, Stas Helene G, Tramper-Stranders Gerdien, Kleinlugtenbeld Elly A, van Kempen Anne A M W, Wessels Margreet, van Rossem Maaike C, Dassel Carin A C M, Pajkrt Dasja, Bonten Marc J M, Bruijning-Verhagen Patricia C J 22 Nov 2021, In: Pediatrics. 148
Pittet Laure F, Messina Nicole L, Gardiner Kaya, Orsini Francesca, Abruzzo Veronica, Bannister Samantha, Bonten Marc, Campbell John L, Croda Julio, Dalcolmo Margareth, Elia Sonja, Germano Susie, Goodall Casey, Gwee Amanda, Jamieson Tenaya, Jardim Bruno, Kollmann Tobias R, Guimarães Lacerda Marcus Vinícius, Lee Katherine J, Legge Donna, Lucas Michaela, Lynn David J, McDonald Ellie, Manning Laurens, Munns Craig F, Perrett Kirsten P, Prat Aymerich Cristina, Richmond Peter, Shann Frank, Sudbury Eva, Villanueva Paola, Wood Nicholas J, Lieschke Katherine, Subbarao Kanta, Davidson Andrew, Curtis Nigel, 28 Oct 2021, In: BMJ Open. 11 , p. 1-9
Winkel Beatrice, Schram Emma, Gremmels Hendrik, Debast Sylvia, Schuurman Rob, Wensing Annemarie, Bonten Marc, Goedhart Edwin, Hofstra Marije 13 Oct 2021, In: BMJ Open. 11 , p. 1-6
Aarestrup Frank M, Bonten Marc, Koopmans Marion Oct 2021, In: The Lancet Regional Health - Europe. 9 , p. 1-4
van Dongen Josephine A P, Rouers Elsbeth D M, Bonten Marc J M, Bruijning-Verhagen Patricia C J, 7 Sep 2021, In: Vaccine. 39 , p. 6151-6156 6 p.
Verberk Janneke D.M., Van Der Kooi Tjallie I.I., Derde Lennie P.G., Bonten Marc J.M., De Greeff Sabine C., Van Mourik Maaike S.M. 18 Aug 2021, In: BMJ Open. 11 , p. 1-9